Melanoma's deadly march to the brain: by what route, and can it be stopped?
- PMID: 21472703
- PMCID: PMC12771280
- DOI: 10.1002/cncr.25716
Melanoma's deadly march to the brain: by what route, and can it be stopped?
Abstract
Melanoma patients who develop brain metastasis have a very poor prognosis, in part because of relative resistance to external beam radiotherapy and in part due to the low activity and poor CNS penetration of the available systemic agents. Three articles in this issue of Cancer summarize retrospective analyses of melanoma patients with brain metastasis. While the three articles investigate similar questions, each article considers different patient characteristics, and the results of the articles provide different and diverging conclusions. We will summarize the results and authors’ conclusions from each of the three articles, examine potential limitations of each article’s conclusions, try to synthesize the results of the three articles, and conclude with ideas for future research.
Comment on
-
Prognostic factors for survival in melanoma patients with brain metastases.Cancer. 2011 Apr 15;117(8):1687-96. doi: 10.1002/cncr.25634. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960525
-
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.Cancer. 2011 Apr 15;117(8):1697-703. doi: 10.1002/cncr.25631. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472716
-
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.Cancer. 2011 Apr 15;117(8):1711-20. doi: 10.1002/cncr.25643. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472718 Free PMC article.
References
-
- Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;116:1697–1703. - PubMed
-
- Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;116:1687–1696. - PubMed
-
- Balch CM, Buzaid AC, Soong S-J, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001;19(16): 3635–48. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
